T1	PROC 0 86	Estudio exploratorio de fase Ib/IIa, multicéntrico, abierto, de combinación innovadora
T2	PROC 92 157	evaluar la seguridad, farmacocinética, farmacodinámica y eficacia
T3	CHEM 172 180	CC-92480
T4	CHEM 182 192	BMS-986348
T5	PROC 197 223	combinaciones terapéuticas
T6	LIVB 239 252	participantes
T7	DISO 257 298	mieloma múltiple recidivante o resistente
#1	AnnotatorNotes T7	C0026764; Multiple Myeloma; Neoplastic Process
T8	PROC 303 338	ensayo para determinar la seguridad
T9	CHEM 342 350	CC-92480
T10	CHEM 373 383	compuestos
#2	AnnotatorNotes T10	C0220806; Chemicals; Chemical
T11	LIVB 397 405	personas
#3	AnnotatorNotes T11	C0027361; Persons; Population Group
T12	DISO 410 426	mieloma múltiple
#4	AnnotatorNotes T12	C0026764; Multiple Myeloma; Neoplastic Process
T13	Neg_cue 431 433	no
T14	Negated 434 442	responde
T15	PROC 455 466	tratamiento
#5	AnnotatorNotes T15	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T16	PROC 507 518	tratamiento
#6	AnnotatorNotes T16	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T17	DISO 543 584	Mieloma múltiple recidivante o resistente
#7	AnnotatorNotes T17	C0026764; Multiple Myeloma; Neoplastic Process
T18	DISO 586 590	MMRR
T19	DISO 613 642	Cancer de células plasmáticas
T20	LIVB 672 685	participantes
T21	PROC 787 823	Consentimiento informado por escrito
T22	PROC 851 875	procedimiento de estudio
T23	Age 880 889	≥ 18 años
T24	LIVB 941 953	participante
T25	DISO 976 978	MM
#8	AnnotatorNotes T25	C0026764; Multiple Myeloma; Neoplastic Process
T26	DISO 983 1018	enfermedad recidivante o resistente
#9	AnnotatorNotes T26	C0012634; Disease; Disease or Syndrome | C0221423; Illness (finding); Sign or Symptom
T27	DISO 1036 1063	progresión de la enfermedad
#10	AnnotatorNotes T27	C0242656; Disease Progression; Pathologic Function
T28	DISO 1162 1169	Mieloma
#11	AnnotatorNotes T28	C0026764; Multiple Myeloma; Neoplastic Process | C0037930; Spinal Cord Neoplasms; Neoplastic Process
T29	PROC 1245 1256	tratamiento
#12	AnnotatorNotes T29	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T30	DISO 1265 1272	mieloma
#13	AnnotatorNotes T30	C0026764; Multiple Myeloma; Neoplastic Process | C0037930; Spinal Cord Neoplasms; Neoplastic Process
T31	DISO 1293 1304	intolerante
T32	Neg_cue 1307 1309	no
T33	Negated 1314 1323	candidato
T34	PROC 1333 1345	tratamientos
#14	AnnotatorNotes T34	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T35	DISO 1418 1420	MM
#15	AnnotatorNotes T35	C0026764; Multiple Myeloma; Neoplastic Process
T36	LIVB 1429 1442	participantes
T37	DISO 1455 1473	enfermedad medible
T38	LIVB 1480 1492	participante
T39	PROC 1505 1521	estado funcional
T40	PROC 1661 1691	Plan de Prevención de Embarazo
T41	PROC 1693 1696	PPP
T42	DISO 1783 1822	compromiso del sistema nervioso central
T43	ANAT 1824 1827	SNC
T44	DISO 1832 1834	MM
#16	AnnotatorNotes T44	C0026764; Multiple Myeloma; Neoplastic Process
T45	DISO 1839 1870	Leucemia de células plasmáticas
#17	AnnotatorNotes T45	C0023484; Leukemia, Plasma Cell; Neoplastic Process
T46	DISO 1872 1904	macroglobulinemia de Waldenstrom
#18	AnnotatorNotes T46	C0024419; Waldenstrom Macroglobulinemia; Neoplastic Process
T47	DISO 1906 1932	síndrome de polineuropatía
T48	DISO 1934 1947	organomegalia
#19	AnnotatorNotes T48	C4054315; Organomegaly; Finding
T49	DISO 1949 1963	endocrinopatía
#20	AnnotatorNotes T49	C0014130; Endocrine System Diseases; Disease or Syndrome
T50	DISO 1965 1975	proteína M
T51	DISO 1978 1996	cambios en la piel
T52	DISO 1998 2003	POEMS
#21	AnnotatorNotes T52	C0085404; POEMS Syndrome; Disease or Syndrome
T53	DISO 2008 2036	amiloidosis de cadena ligera
#22	AnnotatorNotes T53	C0268381; Primary amyloidosis; Neoplastic Process
T54	DISO 2068 2100	Deterioro de la función cardíaca
T55	DISO 2103 2122	enfermedad cardíaca
#23	AnnotatorNotes T55	C0018799; Heart Diseases; Disease or Syndrome
T56	LIVB 2157 2169	participante
T57	DISO 2180 2211	infección previa por SARS-CoV-2
T58	Duration 2222 2233	los 14 días
T59	DISO 2239 2279	infecciones asintomáticas o sintomáticas
T60	Duration 2288 2295	28 días
T61	DISO 2301 2313	enfermedades
#24	AnnotatorNotes T61	C0012634; Disease; Disease or Syndrome | C0221423; Illness (finding); Sign or Symptom
T62	Date 2349 2354	día 1
T63	PROC 2390 2397	terapia
#25	AnnotatorNotes T63	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T64	CHEM 2409 2417	CC-92480
T65	PROC 2447 2458	tratamiento
#26	AnnotatorNotes T65	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T66	CHEM 2470 2478	CC-92480
T67	CHEM 2480 2492	tazemetostat
#27	AnnotatorNotes T67	C4086895; tazemetostat; Organic Chemical · Pharmacologic Substance
T68	CHEM 2494 2504	BMS-986158
T69	CHEM 2507 2517	trametinib
#28	AnnotatorNotes T69	C2697961; trametinib; Organic Chemical · Pharmacologic Substance
T70	PROC 2545 2575	alotrasplante de células madre
T71	PROC 2610 2641	autotrasplante de células madre
T72	Duration 2652 2666	las 12 semanas
T73	PROC 2693 2704	tratamiento
#29	AnnotatorNotes T73	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T74	Duration 2768 2779	los 14 días
T75	PROC 2805 2816	tratamiento
#30	AnnotatorNotes T75	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T76	PROC 2833 2846	Plasmaféresis
#31	AnnotatorNotes T76	C0032134; Plasmapheresis; Therapeutic or Preventive Procedure
T77	PROC 2850 2857	Cirujía
T78	PROC 2872 2884	Radioterapia
#32	AnnotatorNotes T78	C0041626; Ultraviolet Therapy; Therapeutic or Preventive Procedure | C1522449; Therapeutic radiology procedure; Therapeutic or Preventive Procedure
T79	Neg_cue 2885 2896	distinta de
T80	PROC 2900 2913	terapia local
T81	Negated 2900 2913	terapia local
T82	DISO 2919 2933	lesiones óseas
#33	AnnotatorNotes T82	C0238792; Bone lesion; Disease or Syndrome
T83	DISO 2947 2954	mieloma
#34	AnnotatorNotes T83	C0026764; Multiple Myeloma; Neoplastic Process | C0037930; Spinal Cord Neoplasms; Neoplastic Process
T84	PROC 2975 3012	tratamiento farmacológico antimieloma
#35	AnnotatorNotes T84	C0013216; Pharmacotherapy; Therapeutic or Preventive Procedure
T85	Route 3013 3022	sistémico
T86	CHEM 3040 3063	agente en investigación
T87	Duration 3074 3085	los 28 días
T88	Duration 3088 3102	5 vidas medias
T89	PROC 3146 3157	tratamiento
#36	AnnotatorNotes T89	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T90	CHEM 3175 3190	Vacuna COVID-19
T91	Duration 3201 3212	los 14 días
T92	PROC 725 732	estudio
T93	PROC 930 933	ICF
T94	DISO 1738 1755	Compromiso activo
T95	PROC 3162 3169	estudio
T96	DISO 1185 1192	Myeloma
T97	PROC 1624 1628	ECOG
T98	CHEM 1701 1709	CC-92480
T99	PROC 2709 2716	estudio
T100	PROC 2821 2828	estudio
T101	Date 3226 3230	C1D1
T102	Date 2356 2360	C1D1
T103	Negated 2251 2264	asintomáticas
T104	Observation 274 285	recidivante
T105	Observation 288 298	resistente
T106	Observation 434 442	responde
T107	Observation 472 481	regresado
T108	Observation 560 571	recidivante
T109	Observation 574 584	resistente
T110	Observation 690 732	elegibles para ser incluidos en el estudio
T111	Observation 994 1005	recidivante
T112	Observation 1008 1018	resistente
T113	Observation 1280 1291	refractario
T114	Observation 1397 1414	beneficio clínico
T115	CONC 1531 1586	Grupo Oncológico Cooperativo del Este de Estados Unidos
T116	CONC 1588 1622	Eastern Cooperative Oncology Group
T117	CONC 1624 1628	ECOG
T118	Result_or_Value 1633 1638	0 o 1
T119	Observation 1738 1748	Compromiso
T120	Quantifier_or_Qualifier 1749 1755	activo
T121	Quantifier_or_Qualifier 2037 2063	clínicamente significativa
T122	Quantifier_or_Qualifier 2123 2149	clínicamente significativa
T123	Quantifier_or_Qualifier 2280 2285	leves
T124	CONC 2682 2704	inicio del tratamiento
T125	Quantifier_or_Qualifier 2858 2868	importante
T126	Patient 239 252	participantes
T127	Patient 397 405	personas
T128	Patient 672 685	participantes
T129	Future 719 732	en el estudio
T130	Patient 941 953	participante
T131	History_of 976 978	MM
T132	History_of 1245 1256	tratamiento
T133	History_of 1293 1304	intolerante
T134	Patient 1429 1442	participantes
T135	Patient 1480 1492	participante
T136	History_of 1783 1822	compromiso del sistema nervioso central
T137	History_of 1824 1827	SNC
T138	Patient 2157 2169	participante
T139	History_of 2180 2189	infección
T140	History_of 2197 2211	por SARS-CoV-2
T141	History_of 2390 2397	terapia
T142	History_of 2409 2417	CC-92480
T143	History_of 2447 2458	tratamiento
T144	History_of 2470 2478	CC-92480
T145	History_of 2480 2492	tazemetostat
T146	History_of 2494 2504	BMS-986158
T147	History_of 2507 2517	trametinib
T148	History_of 2545 2575	alotrasplante de células madre
T149	History_of 2610 2641	autotrasplante de células madre
T150	History_of 3040 3063	agente en investigación
T151	History_of 1738 1748	Compromiso
